Testing a new immune cell therapy for hard-to-treat blood cancer

Plain-English translation of NCT05722418 on ClinicalTrials.gov ↗ · Source last updated September 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing , a new type of treatment that uses your own immune cells that have been specially edited and trained in a lab to fight multiple myeloma. The study will first figure out the safest and most effective dose of this medication, then test how well it works for people whose cancer has returned or stopped responding to other treatments.

Multiple myeloma can come back or stop working with standard treatments, leaving patients with few options. This trial exists to see whether this new approach — using edited immune cells — might offer hope for people in that situation.

Do you qualify?

You likely qualify if…

you have been diagnosed with multiple myeloma that has come back or is no longer responding to treatment
you have already tried at least 3 different treatment lines, including specific types of cancer drugs
you are in good enough health to tolerate the treatment (your doctor will check this carefully)
you have measurable disease that can be tracked during the study

You likely don't qualify if…

you have previously received any type of CAR-T cell therapy
you had a stem cell transplant within the last 6 weeks or 6 months (depending on the type)
you have or had involvement of the cancer in your central nervous system (brain or spinal cord)
you have hepatitis B or C, or HIV infection
you have had a stroke or seizure in the last 6 months

What participation looks like

The study has two parts. First, doctors will test increasing doses of the medication in small groups to find the safest dose. Then, about 30 more participants will receive the medication at that dose to see how well it works. You'll need to visit the hospital for the treatment and for follow-up appointments to monitor how you respond and watch for any side effects.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(16 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

CU Anschutz Medical Campus, Anshutz Cancer Pavillion, Aurora, Colorado

Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, Florida

University of Kentucky/ Markey Cancer Center, Lexington, Kentucky

Hackensack Meridian John Theurer Cancer Center, Hackensack, New Jersey